Molecular Characteristics
Complete Specifications
Structural Composition
Modified 29-amino-acid GRF (1–29) sequence with substitutions at positions 2, 8, 15, and 27 to enhance stability
Physical Properties
CJC-1295 (No DAC) is a modified 29-amino-acid peptide derived from growth hormone–releasing factor (GRF 1–29). Targeted amino acid substitutions enhance resistance to enzymatic degradation while preserving the core structural framework. Unlike DAC-conjugated versions, this variant does not include a drug affinity complex moiety, resulting in a shorter structural persistence profile under research conditions. Lyophilized presentation supports stability during storage, and protection from moisture, light, and repeated freeze–thaw cycles helps maintain peptide integrity for laboratory and analytical applications.
Research Applications
Growth Hormone Releasing Hormone (GHRH) Research
CJC-1295 (No DAC) is utilized as a research compound in studies examining growth hormone–releasing hormone (GHRH) receptor signaling and pulsatile endocrine regulation. Laboratory investigations focus on its role in:
- GHRH Receptor Activation Models: Investigation of receptor binding dynamics and downstream signaling cascades
- Pulsatile Growth Hormone Signaling: Evaluation of transient hormone release patterns under experimental conditions
- cAMP Pathway Studies: Analysis of intracellular signaling mechanisms triggered by GHRH receptor engagement
- Endocrine Feedback Loop Research: Examination of regulatory pathways influencing pituitary hormone dynamics
- Short-Acting Peptide Kinetics: Investigation of receptor interaction duration and signaling half-life characteristics
Experimental protocols commonly employ receptor-binding assays, pituitary cell cultures, and hormone secretion models to characterize CJC-1295 (No DAC)–mediated signaling responses.
Endocrine and Metabolic Research
CJC-1295 (No DAC) has been extensively studied in research models examining endocrine regulation and metabolic signaling. Key areas of investigation include:
- Insulin-Like Growth Factor (IGF) Signaling Models: Evaluation of downstream pathways associated with growth hormone–mediated signaling
- Protein Synthesis Pathway Research: Investigation of intracellular signaling influencing anabolic processes
- Lipid and Glucose Interaction Studies: Analysis of metabolic cross-regulation in response to endocrine signaling
- Energy Utilization Models: Research into systemic energy balance under growth hormone modulation
- Hormonal Pulse Pattern Analysis: Examination of physiological timing and amplitude of hormone release
This body of research utilizes endocrine profiling, metabolic assays, and longitudinal hormone monitoring systems to evaluate signaling outcomes.
Peptide Pharmacokinetics and Signal Duration Research
CJC-1295 (No DAC) is also examined in studies focused on short-acting peptide kinetics and receptor engagement duration, including:
- Receptor Binding Affinity Studies: Evaluation of interaction strength with GHRH receptors
- Signal Onset and Duration Models: Investigation of transient signaling characteristics compared to long-acting analogs
- Peptide Stability Analysis: Research into degradation kinetics and plasma persistence under laboratory conditions
- Comparative Signaling Profiles: Examination of receptor activation patterns relative to extended-duration analogs
Laboratory protocols assess pharmacokinetic characteristics, receptor occupancy, and signal attenuation using biochemical and analytical techniques.
Cellular Signaling and Growth Pathway Research
Additional research applications explore CJC-1295 (No DAC)’s influence on intracellular growth-related signaling systems, including:
- MAPK and PI3K Pathway Studies: Investigation of downstream cascades associated with growth hormone signaling
- Gene Expression Profiling: Analysis of transcriptional responses linked to endocrine modulation
- Cellular Adaptation Mechanisms: Research into adaptive responses to pulsatile hormone signaling
- Homeostatic Regulation Systems: Examination of feedback mechanisms preserving endocrine balance
Research in this domain focuses on understanding how CJC-1295 (No DAC) modulates GHRH receptor signaling, endocrine pulse patterns, and downstream growth-related pathways under controlled experimental conditions.
Laboratory Handling and Storage Protocols
Lyophilized Powder Storage
- Store at –20°C to –80°C in the original, sealed vial
- Protect from light exposure and moisture
- A desiccated storage environment is recommended
- Stability data suggests extended stability when stored at −20 °C or below.
Reconstituted Solution Storage
- Short-term storage: Up to 7 days at 4°C
- Long-term storage: Store at –20°C in aliquots
- Use single-use aliquots to preserve peptide integrity
- Minimize freeze–thaw cycles; single-use aliquots are strongly recommended
Stability Characteristics
CJC-1295 (No DAC) is a synthetic peptide research compound that demonstrates stable handling characteristics when managed according to standard peptide laboratory protocols. Proper cold storage of the lyophilized material, careful reconstitution, and minimized freeze–thaw exposure help preserve structural integrity and solubility. When handled appropriately, CJC-1295 (No DAC) supports consistent use in in vitro and analytical research applications.
Frequently Asked Questions
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a modified GHRH analog studied in laboratory settings for its ability to activate GHRH receptors and influence downstream growth hormone signaling pathways in preclinical research models.
What does “No DAC” mean?
“No DAC” indicates that the peptide does not include the Drug Affinity Complex modification that extends half-life in research models. As a result, CJC-1295 (No DAC) typically demonstrates a shorter duration of activity compared to CJC-1295 with DAC.
What is CJC-1295 (No DAC) commonly researched for?
In experimental research environments, it is studied for:
-
GHRH receptor activation
-
Growth hormone pulsatility models
-
IGF-1 pathway research
-
Endocrine signaling pathway investigation
All applications are exploratory and conducted in preclinical or laboratory settings.
How does CJC-1295 (No DAC) differ from CJC-1295 with DAC?
The primary difference is the presence of the Drug Affinity Complex (DAC) in the extended version. The DAC modification allows binding to serum albumin in research models, extending circulation time. The No DAC version lacks this modification and therefore has a shorter activity window in comparative studies.
How is CJC-1295 (No DAC) supplied?
CJC-1295 (No DAC) is typically supplied as a lyophilized (freeze-dried) powder in sealed research vials to maintain stability during storage and shipment.
How should unreconstituted CJC-1295 (No DAC) be stored?
Lyophilized peptide should be stored:
-
Long-term: −20 °C to −80 °C
-
Short-term: 2–8 °C
Keep vials sealed and protected from light and moisture.
How should reconstituted CJC-1295 (No DAC) be handled and stored?
Once reconstituted:
-
Store at 2–8 °C for short-term laboratory use
-
For longer-term storage, aliquot and freeze at −20 °C or below
-
Minimize freeze–thaw cycles using single-use aliquots
-
Gently swirl to mix; avoid vigorous agitation
Is CJC-1295 (No DAC) FDA-approved?
No. CJC-1295 (No DAC) is not FDA-approved as a drug, supplement, or therapeutic product. It is sold exclusively as a research compound and must not be marketed or used for diagnostic, therapeutic, or consumption purposes.
Does CJC-1295 (No DAC) require a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis (COA) should be available for each batch, confirming peptide identity, purity, and analytical testing results to support research quality and traceability.
Research Background
For a referenced overview of what the published research examines — including why the human trials used only the DAC form, and what the literature does not establish — see What Is CJC-1295? Research Background, and DAC vs No DAC. It cites peer-reviewed sources and contains no dosing guidance.
This product is not for human consumption. It is sold strictly for research and educational purposes and is not intended to diagnose, treat, cure, or prevent any disease.
Any clinical data or research information referenced on this page is derived from peer-reviewed scientific literature and official publications. This information is provided for educational reference only and does not constitute medical advice or product claims.
By purchasing this product, you acknowledge that you are a qualified researcher and agree to use it in full compliance with all applicable laws and regulations.
